Humacyte (HUMA) Insiders Show Confidence Despite Stock Decline
Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024
Humacyte to Present Efficacy and Safety Results From V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
Insider Buyers At Humacyte Likely Disappointed With 17% Slide
Promising Clinical Outcomes and Imminent FDA Approval Bolster Buy Rating for Humacyte's Bioengineered Vessel
